1 5 6 9 a r t I C l e S Arginine vasopressin (AVP) has well-known roles in the regulation of varied biological systems, with its effects being mediated by one of three receptors: V1AR, V1BR or V2R 1,2 . V1AR is believed to predominate in the CNS 3 , and its involvement in affiliation and social communication in microtine rodents 4 and humans 5,6 is known to be male specific and genetically determined. In humans, two studies using intranasal AVP analogs observed either no 7 or modest effects on acute pain 8 . In rodents, AVP produces clear, but modest, inhibition of acute thermal pain after systemic, supraspinal or spinal injection in rodents, but most of the evidence suggests that this analgesia is mediated by V1BR 9 or V2R 10,11 .
Arginine vasopressin (AVP) has well-known roles in the regulation of varied biological systems, with its effects being mediated by one of three receptors: V1AR, V1BR or V2R 1, 2 . V1AR is believed to predominate in the CNS 3 , and its involvement in affiliation and social communication in microtine rodents 4 and humans 5, 6 is known to be male specific and genetically determined. In humans, two studies using intranasal AVP analogs observed either no 7 or modest effects on acute pain 8 . In rodents, AVP produces clear, but modest, inhibition of acute thermal pain after systemic, supraspinal or spinal injection in rodents, but most of the evidence suggests that this analgesia is mediated by V1BR 9 or V2R 10, 11 .
Pain and analgesic responses in humans and rodents feature robust inter-individual variability, and the responsible genes are just starting to be identified 12 . An explicit rodent-to-human translational strategy was successfully employed on a few occasions in this domain [13] [14] [15] [16] . We found that the mouse Avpr1a gene (encoding V1AR) is responsible for variable pain sensitivity to formalin and capsaicin. Translation of this finding to humans revealed that V1AR's role in pain interacts not only with genotype, but with sex and acute stress, and this interaction was then confirmed and explained in the mouse.
RESULTS

Positional refinement of a formalin test gene
Standard inbred mouse strains display robust variability on virtually all nociceptive assays 17, 18 , including on the formalin test, a widely used assay of spontaneous, tonic chemical/inflammatory nociception 19 . Using an F 2 intercross between the phenotypically divergent A/J (resistant) and C57BL/6J (sensitive) strains, we previously identified a quantitative trait locus (QTL), which we named Nociq2, on distal mouse chromosome 10 (>58 cM), which was associated with variability in the late/tonic phase (10-60 min post-injection) of the formalin test 20 . A recent QTL mapping study of the related acetic acid abdominal constriction test also identified substantial linkage in this region 21 .
We used a variety of strategies to confirm and refine the position of the QTL, including the testing of recombinant congenic strains 22 and the breeding and testing of marker-assisted congenic and subcongenic strains. A comparison of the formalin test phenotype and chromosome 10 genotype of these strains confirmed that the responsible polymorphism(s) could only lie between DNA markers D10Mit25 (at 121.781 Mb) and D10Mit103 (at 125.176 Mb) ( Supplementary Figs. 1-3) .
Quantitative trait locus mapping of chemical/inflammatory pain in the mouse identified the Avpr1a gene, which encodes the vasopressin-1A receptor (V1AR), as being responsible for strain-dependent pain sensitivity to formalin and capsaicin. A genetic association study in humans revealed the influence of a single nucleotide polymorphism (rs10877969) in AVPR1A on capsaicin pain levels, but only in male subjects reporting stress at the time of testing. The analgesic efficacy of the vasopressin analog desmopressin revealed a similar interaction between the drug and acute stress, as desmopressin inhibition of capsaicin pain was only observed in nonstressed subjects. Additional experiments in mice confirmed the male-specific interaction of V1AR and stress, leading to the conclusion that vasopressin activates endogenous analgesia mechanisms unless they have already been activated by stress. These findings represent, to the best of our knowledge, the first explicit demonstration of analgesic efficacy depending on the emotional state of the recipient, and illustrate the heuristic power of a bench-to-bedside-to-bench translational strategy. Table 1 ). Of these, the only obvious candidate was Avpr1a, although no attempt was made to rule out the others functionally. Instead, we conducted a haplotype mapping analysis comparing the late-phase formalin test phenotypes of 16 strains ( Fig. 1a) with inheritance of single nucleotide polymorphisms (SNPs) throughout the region. We investigated SNP haplotype patterns in the Mouse Phenome Database highdensity SNP map (≈8 million, CGD1 imputed 74-strain dataset, http:// phenome.jax.org/SNP/) in the 3.4-Mb linked region. We found a large number of SNPs in the proximal part of this region featuring two haplotypes with perfect alignment with formalin sensitivity (Fig. 1b) . We then examined individual SNPs in this region, in 100-kb intervals. Of SNPs observed to be polymorphic among the 16 strains tested, a very high percentage showed perfect correspondence in the 121.7-121.8 Mb region ( Supplementary Table 2 ), with smaller numbers of perfectly corresponding SNPs between 122.1-122.3 Mb (Fig. 1c) . Only two genes lie near these regions: Avpr1a (121.886 Mb) and Ppm1h (122.115 Mb). Strains with the C57BL/6J-like (high phenotypic) haplotype at SNPs in the 121.7-121.8 Mb region (for example, rs29348576 at 121.75 Mb) exhibited more than double the pain behavior of strains with the A/J-like (low phenotypic) haplotype (24.7 ± 1.0 versus 11.8 ± 0.7% samples featuring licking, t 246 = 9.4, P < 0.001).
Avpr1a affects inflammatory pain sensitivity in mice Given that multiple polymorphic SNPs exist upstream of Avpr1a and that no SNPs are polymorphic between the A/J and C57BL/6J strains in the coding region of the gene itself, it is likely that one or more of these SNPs are affecting the expression of Avpr1a. Quantitative real-time reverse-transcription PCR experiments confirmed the differential basal expression of Avpr1a between the strains in multiple regions of the CNS and the liver ( Fig. 2a) . As the A/J mice, the painresistant strain, displayed higher Avpr1a expression than C57BL/6J, we tentatively conclude that higher basal expression is protective against pain (that is, analgesic).
This would predict that a Avpr1a −/− mutant would be more sensitive to late-phase formalin nociception than a wild-type mouse (C57BL/ 6J), and that is what we observed (F 2,38 = 3.4, P < 0.05; Fig. 2b ), providing causal evidence of the gene's involvement in the trait. There were no genotype differences in early phase behavior or edema (data not shown). We tested the Avpr1a −/− mice on a battery of nociceptive assays (data reported in ref. 23) and no other significant genotype differences were observed (P > 0.05), except on the capsaicin (2.5 µg) test, another chemical assay featuring spontaneous licking behavior, in which null mutants again displayed higher pain-related behavior (F 2,36 = 4.1, P < 0.05; Fig. 2c ). We have not formally excluded a role for Ppm1h in inflammatory pain, but this gene is not known to be expressed in any pain-relevant loci (http://biogps.gnf.org/).
AVPR1A associations interact with sex and stress
To determine whether the human AVPR1A gene is involved in variable responses to pain, we genotyped two SNPs in the small (<6.4 kb) gene (rs1042615 and rs10877969; contained in the single Genomic location (Mb) 1 No genetic association with either SNP was seen in overall mean pain ratings ( Fig. 3a and data not shown) or in ratings of stress (n = 61) at the time of testing ( Fig. 3b and data not shown). However, for the promoter SNP, rs10877969, we observed a significant three-way interaction between genotype, stress level and sex (F 1,53 = 5.2, P < 0.05), such that, in male subjects reporting stress, pain ratings were lower in those with the GG/GA genotype compared with the AA genotype ( Fig. 3c) . We found no effects of stress or genotype in women ( Fig. 3d) . Allele frequencies of rs10877969 differed in Caucasian and Asian versus African-American subjects, and the lower pain ratings of male GG/GA subjects were not observed among the latter racial group (Supplementary Fig. 4 ).
The overall results remained significant regardless of whether data from African-American subjects were included (P < 0.05). Factor analysis of components explaining the temporally dynamic capsaicin pain response 24 revealed a factor representing the influence of stress on capsaicin pain; we observed a significant sex × genotype interaction (genotype effect in males only) in this stress-induced analgesia factor (P < 0.05; Supplementary Fig. 5 ).
The demonstrated involvement of AVPR1A in capsaicin pain suggests that vasopressin may have analgesic properties against this pain modality. We administered the synthetic vasopressin analog desmopressin (1-desamino-8-d-arginine vasopressin, 50 µg), or saline (0.5 ml) intranasally to human subjects 25 min before pain testing with topical capsaicin (8%, applied to a 3-cm 2 area overlying the ventral forearm). Subjects gave ratings on a 0-100 scale every 10 min post-capsaicin administration for 50 min, and these ratings were averaged. We also measured pressure and heat pain thresholds, and heat pain tolerance, before and after drug administration. Notably, the experiment occurred on two testing days per subject; the design was randomly counterbalanced such that half the subjects received desmopressin on the first day and half on the second day. Overall, there was absolutely no effect of desmopressin on capsaicin pain ratings compared to saline ( Fig. 4a ). However, we noticed a marked and robust interaction between the apparent efficacy of desmopressin and the order in which subjects completed the experiment (F 1,36 = 15.4, P = 0.0004); in those receiving saline on the first day and desmopressin on the second, desmopressin produced significant analgesia (P < 0.05), whereas desmopressin was completely inefficacious in those receiving desmopressin on the first day and saline on the second day (P = 0.26; Fig. 4b) .
The interaction between pain and stress noted previously suggested a hypothesis. On the first testing day, subject stress levels might be higher, as subjects had no prior experience with capsaicin pain and might fear its intensity, leading to stress-induced analgesia. On the second testing day, having already experienced capsaicin and realizing that pain levels are modest (less than 30 on the 1-100 scale at peak), desmopressin produced significant analgesia for low-stress subjects, but no effect of desmopressin emerged among high-stress subjects. *P < 0.05 compared with vehicle. Data are presented as in b. (d-g) The correlation of desmopressin analgesia (expressed as saline-desmopressin difference scores in mean NRS scores, positive values represent desmopressin analgesia) with stress levels (0-10) was only seen in male subjects with the AA genotype at rs10877969 in AVPR1A. The order of drug administration interacted significantly with drug condition, such that desmopressin was highly efficacious in those receiving it in the second session (Veh→DES), but not among those receiving it in the first session (DES→Veh). Data are presented as mean ± s.e.m. NRS scores averaged over the 50-min testing period. ***P < 0.001 compared with vehicle (veh). (c) Using a mean split, subjects were divided into high-versus low-stress groups, which revealed a significant stress × drug interaction, such that a r t I C l e S stress levels would be low and thus no stress-induced analgesia would be present. Indeed, regardless of drug, stress ratings (on a scale of 1-10, immediately before capsaicin) decreased significantly (F 1,37 = 5.7, P < 0.05) from the first to second testing day (day 1, 3.4 ± 0.4 out of 10; day 2, 2.3 ± 0.3 out of 10). We reanalyzed the data using a mean split of stress ratings irrespective of testing order and again observed that desmopressin produced significant analgesia when stress levels were low, but not when stress levels were high (F 1,37 = 7.1, P = 0.01; Fig. 4c) . These effects were similar in both sexes, with the exception of a strongly trending (P = 0.06) interaction between drug and sex such that males given desmopressin on the first testing day displayed the highest stress levels (4.8 out of 10) of all groups, consistent with findings that intranasal vasopressin elevated anxiety to neutral stimuli in men, but not women 5 . We found that the relationship between stress and desmopressin analgesia also interacts with sex and genotype, with a significant correlation between stress and analgesia (r = -0.62, P < 0.01) only observed in men with the AA genotype of rs10877969 ( Fig. 4d-g) . All of these effects were specific to capsaicin pain; we observed no analgesic effects of desmopressin or interactions with sex, stress or genotype for heat or pressure pain (Supplementary Fig. 6 ).
AVP-and stress-Induced analgesia in mice
We then investigated whether vasopressin analgesia interacts with stress and genotype in mice as well as in humans. It is well known in the rat that the novelty of the testing situation can produce stressinduced analgesia that can be ameliorated by prior habituation to the environment [25] [26] [27] , and this struck us as highly analogous to the apparent situation in the human desmopressin study. We explicitly compared the ability of AVP (0.1 mg per kg of body weight, subcutaneous) to inhibit capsaicin-induced licking behavior in male mice that were either habituated to the testing room and observation cylinders six times (each for 60 min) or were naive to the testing room (that is, not habituated). In a marked parallel to the human study, AVP was highly efficacious in habituated mice, but produced no significant analgesia in non-habituated mice (drug × habituation, F 1,23 = 4.7, P < 0.05; Fig. 5a ). The AVP analgesia was mediated via V1AR, as no analgesia could be evinced in Avpr1a −/− mice (Supplementary Fig. 7) . Decreased licking behavior of saline-treated mice in the nonhabituated condition compared with the habituated condition revealed the existence of stress-induced analgesia in the former (Fig. 5a) . The influence of Avpr1a gene deletion on capsaicin pain behavior (and formalin pain behavior, data not shown) depended on habituation status; we replicated the increased sensitivity of knockout mice in a new cohort of nonhabituated male mice, but no genotype differences were seen in habituated mice (genotype × habituation, F 1,13 = 5.3, P < 0.05; Fig. 5b ). That habituation reduces stress was demonstrated by changes in fecal boli, plasma corticosterone levels and plasma vasopressin levels (Supplementary Fig. 8) .
The finding that only nonhabituated Avpr1a mutants would differ from wild types would be predicted if mutant mice were unable to produce stress-induced analgesia that would otherwise decrease pain behavior. Accordingly, we found that male Avpr1a −/− mice were deficient in opioid-mediated (that is, naloxone reversible) stressinduced analgesia on the 56 °C hot-plate test 28 produced by forced swimming in 32 °C water (genotype × drug, F 1,21 = 8.2, P < 0.01; Fig. 5c ). Finally, we retested male A/J and C57BL/6J mice on the formalin test with and without habituation; the expected strain difference was observed in the nonhabituated condition, but no strain difference was seen if mice were habituated (genotype × habituation, F 1,17 = 5.3, P < 0.05; Fig. 5d ). As predicted by results in the null mutants, the high Avpr1a-expressing A/J strain displayed evidence of stress-induced analgesia in the nonhabituated condition, whereas the lower-expressing C57BL/6J strain did not. We previously demonstrated a relative deficit in opioid-mediated stress-induced analgesia in male C57BL/6J mice 29 . Ironically, the elucidation of Avpr1a as the gene underlying Nociq2 was wholly reliant on testing-related stress; if habituation had been used originally, no QTL would have been apparent. Nociq2 is not actually a pain QTL, but is instead a stress-induced analgesia QTL. Notably, the interaction between AVP/V1AR and stress appeared in every case described above to be specific to male mice; in female mice, AVP analgesia was seen regardless of habituation status, capsaicin pain and stress-induced analgesia were unaltered in Avpr1a −/− mice, and the A/J versus C57BL/6J strain difference was observed in both the habituated and nonhabituated conditions (Supplementary Fig. 9 ).
DISCUSSION
Taken together, these results suggest that, in both mice and humans, vasopressin, acting on V1AR, produces inhibition of capsaicin-induced pain by activating endogenous (stress induced) analgesic systems unless those same systems have already been activated by stress itself. The likelihood of stress-induced analgesia being present, affecting both pain and desmopressin inhibition of that pain, is in turn strongly influenced by sex and AVPR1A genotype (Supplementary Fig. 10) . Thus, it a r t I C l e S appears that desmopressin analgesia in males results from a three-way interaction between genotype, drug and acute stress. Similarly, capsaicin (and in mice, formalin) pain sensitivity is also influenced, in males, by an interaction between genotype and stress.
To the best of our knowledge, this is the first explicit evidence of the dependence of analgesic efficacy with the acute emotional state of the subject at the time of administration. If the pharmacological efficacy of drugs interacts with both genotype and stress (especially chronic stress), this could have widespread implications for both pharmacotherapy and the design of pharmacological studies. Moreover, these findings demonstrate the utility of the bidirectional (bench to bedside and back to bench) translational approach, as all three research components (murine genetics, human genetics and human pharmacology) provided a crucial piece of information clarifying the analysis of the others, and successfully predicted the results of new, more complex experiments. Although we observed the role of V1ARs in pain to be specific to the chemical/inflammatory modality, most chronic pain states feature inflammation, and the capsaicin test is thought to be an excellent model of human clinical pain 30 . Finally, these data represent yet another example of qualitative differences in the operation of pain mechanisms between the sexes 31 .
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/. 
ONLINE METhODS
mice. Subjects in all experiments were naive, adult (6-12 weeks old) mice of both sexes. Genotypes tested included A/J, C57BL/6J, AcB/BcA-set recombinant congenic strains (AcB63, AcB64, BcA70, BcA72, BcA79, BcA81, BcA86) 22 , and congenic lines described below. Haplotype mapping was performed by phenotyping 14 other inbred strains (all 'J' substrains). Upon weaning (at 18-21 d) or immediately after arrival, mice were housed in standard shoebox cages of 2-4 with same-sex littermates in a temperature-controlled (20 ± 1 °C) environment (14 h:10 h light-dark cycle, lights on at 7:00 a.m.) with ad libitum access to food (Harlan Teklad 8604) and tap water. Mice were habituated to the laboratory for at least 1 week before any behavioral testing commenced.
We used the AcB64 and BcA72 strains to construct speed congenics (A.AcB64 Nociq2 and C57BL/6J.BcA72 Nociq2 lines, respectively); these were generated with marker-assisted selection of breeding males 33 . The purity of the congenic strains was confirmed by genotyping 20 informative microsatellites (CEQ 8000 Genetic Analysis System, Beckman-Coulter) chosen at random throughout the genome.
We used one of the A.AcB64 Nociq2 congenic lines (line 64C1, see Supplementary  Fig. 2) to generate two interval-specific subcongenic lines. We backcrossed the congenic line to A/J mice and searched for crossovers via the observation of heterozygosity at markers distal to D10Mit233 (114.0 Mb). We found one female mouse with heterozygosity at D10Mit297 and D10Mit103, indicating a crossover somewhere between 121.7 Mb and 124.4 Mb (A/J alleles distal to the crossover). This mouse was backcrossed to A/J mice and then intercrossed to form the 64SCA line (AcB64-derived subcongenic line with A/J alleles at distal chromosome 10; Supplementary Fig. 3) . We also found a male mouse with heterozygosity at D10Mit14 and D10Mit237, and used it to reduce the C57BL/6J-derived region of A.AcB64 Nociq2 , forming the 64SCB line (AcB64-derived subcongenic line with C57BL/6J alleles at distal chromosome 10; Supplementary Fig. 3) .
Avpr1a −/− mice and wild-type controls (Avpr1a +/+ ), bred congenic onto a C57BL/6 background for >10 generations, were obtained from the National Institute of Mental Health 34 . Lines were maintained as heterozygote × heterozygote breeding colonies, and all offspring were genotyped by custom PCR analysis of DNA isolated from tail tissue.
Quantitative PcR. We quantified basal mRNA expression of Avpr1a in A/J and C57BL/6J mice (compared to the housekeeping gene Gapdh) in lumbar (L4-L6) dorsal root ganglion, the dorsal horn of the spinal cord, periaqueductal gray, hypothalamus, whole brain (minus cerebellum) and liver. Experiments in all tissues were conducted twice. Tissue was dissected and harvested, and total RNA was isolated and reverse transcribed using standard protocols. Gene expression was quantified using the 7700 Sequence Detector (TaqMan) and the SYBR Green PCR Core Reagent Kit, as described in the manufacturer's manual (Applied Biosystems).
Microarray gene expression profiling data from our laboratory using these two strains suggest that formalin is not a sufficient stimulus to regulate a large number of genes (unpublished observations, J.-S.A. and J.S.M.). It is also questionable as to whether strain differences, which are obvious even at the beginning of the late phase of the formalin test, could be secondary to formalin-induced gene expression changes. Thus, we feel comfortable asserting that basal strain differences in gene expression are likely responsible for phenotypic strain differences in this trait.
Habituation.
In most experiments, mice were not habituated to either the testing room or the Plexiglas testing enclosures before the day of testing. A 30-min habituation was provided to all subjects immediately before testing. Those groups designated as habituated were also placed in the testing room in testing enclosures identical to those to be used in the experiment for 60 min on each of 6 d preceding the experiment, and then returned to the vivarium.
Formalin test. Mice were habituated for 30 min in individual transparent Plexiglas cylinders (15 cm in diameter, 22.5 cm high) placed atop a glass surface suspended over high-resolution video cameras. All subjects were then given a subcutaneous injection of 0.5-5% formalin (vol/vol, Sigma) into the plantar right hindpaw (20 µl) and digitally videotaped for 60 min following the formalin injection. Video files were later sampled for 5 s at 1-min intervals, and the presence or absence of right hindpaw licking/biting in that 5-s period was scored (Noldus Observer). The early (acute) phase of the formalin test was defined as 0-10 min post-injection, and the late (tonic) phase as 10-60 min post-injection. Data are presented as the percentage of samples in which licking/biting was detected (percentage samples licking).
Hindpaw edema was quantified as the difference in the weight of the injected versus uninjected paw, as a percentage of total body weight, as previously described 20 .
mouse capsaicin test. Mice were habituated for 30 min in individual transparent Plexiglas cylinders (15 cm in diameter, 22.5 cm high) placed atop a glass surface above high-resolution video cameras. All subjects were then given a subcutaneous injection of 2.5 µg capsaicin (Sigma) into the plantar right hindpaw (20 µl) and digitally videotaped for 10 min following the formalin injection. Video files were later scored for the total duration (s) of licking/biting of the right hindpaw. Sampling was not used in the capsaicin test because of the short duration of behavioral responses.
Hot-plate test. Mice were gently placed on a metal surface maintained at 56 °C (IITC Model PE34MHC; Stoelting) in a transparent Plexiglas cylinder (15 cm in diameter, 22.5 cm high). The latency to either lick or shake either hind paw was measured with a stop watch as a nocifensive endpoint. mouse stress measures. Stress was estimated in three different ways: fecal boli deposition, plasma corticosterone and plasma AVP. The number of fecal boli deposited at the end of the 30-min habituation period (that is, immediately before formalin or capsaicin injection) was counted. In separate subjects, trunk blood was extracted from mice that were killed at the end of the 30-min habituation period. Plasma was extracted from trunk blood by cold (4 °C) centrifugation (15 min at 20,000g) and immediately frozen at -20 °C. Samples were assayed for corticosterone and AVP by enzyme immunoassay kits, according to manufacturer's instructions (Cayman Chemical, corticosterone kit #500655, AVP kit #583951).
Swim stress-induced analgesia. Immediately following the measurement of baseline latencies on the 56 °C hot-plate test, mice were gently placed in a 2-l cylindrical container that was approximately two-thirds filled with water maintained at 32 ± 1 °C. Escape being impossible, mice swam for 3 min and were removed, dried off and left in a towel-lined cage for 2 min. They were then retested on the hot plate. Analgesia was quantified as the percentage of the maximum possible analgesia using a cut-off latency (not reached by any subject) of 45 s: [(post-swim latency -baseline latency)/(45 -baseline latency)] × 100. mouse drug administration. AVP (Sigma) was administered at a dose of 0.1 mg per kg (subcutaneous) in a volume of 10 ml kg −1 . This dose was chosen on the basis of our recent experience with the compound in multiple genotypes 23 . Naloxone (Sigma) was administered at a dose of 10 mg per kg (subcutaneous) in a volume of 10 ml kg −1 . Control groups received physiological saline at the same volume.
capsaicin pain association study. The sample consisted of 104 healthy adults (51.9% female, mean age = 28.6 ± 8.6 years; self-reported ethnicity: 50.9% Caucasian, 35.2% African American, 13.9% Asian, 94.4% of non-Hispanic origin). Whole blood samples or saliva was obtained for genetic analysis and stored until DNA was extracted. Participants rated their current stress level on a 0 to 10 scale (0 = no stress, 10 = extreme stress) immediately before capsaicin administration. Capsaicin application methods were similar to procedures published previously 35 . A topical cream consisting of 0.35-0.5 g of 10% capsaicin (wt/vol) was applied to a 6.25-cm 2 area on the dorsal aspect of the nondominant hand, and was evenly spread on the skin. Pain rating data were collected over a set interval, up to 90 min. Participants rated their pain continuously on a computerized 0-100 VAS (0 = no pain, 100 = most intense pain imaginable).
We selected two SNP markers in the AVPR1A gene for genotyping, based on relatively high minor allele frequencies and physical location in potentially functional sites: rs1042615, a silent substitution in exon 1 (A/G, TTT to TTC (Phe/Phe) at amino acid 136, could affect RNA stability or splicing), and rs10877969, in the promoter region (could affect gene expression). These markers are validated, have minor allele frequencies greater than 10% in Caucasians and other ethnic groups and they are 3 kb apart (covering most of the gene yet displaying fairly good linkage disequilibrium for haplotyping). The primers and probes for genotyping were from ABI. Genomic DNA was purified using QIAampTM 96 DNA Blood Kit (Qiagen). Genotyping was performed by the 5′ nuclease method 36 using fluorogenic allele-specific probes. Allele-specific signals were distinguished by measuring endpoint 6-FAM or VIC fluorescence intensities at 508 nm and 560 nm, respectively, and genotypes were generated using Sequence Detection System Software (ABI). Genotyping error rate was directly determined by re-genotyping 25% of the samples, randomly chosen, for each locus. The overall error rate was <0.005. Genotype completion rate was 0.98. Allele frequencies were calculated in each sample, and Hardy-Weinberg equilibrium testing using Fisher's exact test was performed by PLINK 37 . Single-marker analyses were conducted for the associations between AVPR1A markers and capsaicin-induced pain scores.
We also applied an established dynamic mathematical model that successfully parsed the marked individual variability in the response to capsaicin stimuli, and with which we detected three common dynamic (that is, temporal) response patterns among human subjects 24, 38 (Supplementary Fig. 5 ). desmopressin analgesia study. We recruited 40 (20 female, 20 male) healthy participants between the ages of 18 and 45 via advertisements and word of mouth, and one female participant failed to complete the study as a result of medical exclusion. Each participated in two testing sessions, one involving desmopressin (Sanofi-aventis) and the other involving saline, administered intranasally in randomly counterbalanced and double-blind fashion. At the outset of each session, tension (that is, stress) ratings were obtained using a visual analog mood scale 39 . Two participants failed to complete the visual analog mood scale correctly and were excluded from analyses involving these data.
Intranasal desmopressin (1-desamino-8-d-arginine vasopressin, a vasopressin analog without the pressor effects of AVP) at a concentration of 100 µg ml −1 of saline was administered using a Pfeiffer SAP#77061 metered spray pump, as a series of five 100-µl sprays, for a total dose of 50 µg. Saline was administered in identical fashion.
In each session, heat pain threshold and tolerance and pressure pain threshold were assessed immediately before and 10 and 50 min after drug administration, using standard methods 40 . We applied capsaicin cream (8%) topically to a 3-cm 2 area of the right ventral forearm 25 min after drug administration. Participants provided pain ratings using a 0 (no pain) to 100 (most intense pain imaginable) NRS every 10 min for 50 min after capsaicin application.
Genomic DNA was purified from saliva samples collected with the Oragene system (DNA Genotek) using the manufacturer's recommended procedure. Genotyping was performed using ABI TaqMan SNP assays for rs10877969 and rs1042615, using the Applied Biosystems 7900HT SNP platform. Genotyping for rs10877969 failed in two subjects, and thus 36 subjects were ultimately available for genotype-phenotype correlation analysis. The G allele frequency was in Hardy-Weinberg equilibrium and was somewhat closer to that reported in dbSNP than to that observed in the capsaicin pain sample set.
For most statistical analyses the mean NRS score over the 50-min testing period was used as a dependent measure; broadly similar results were obtained when substituting other possible dependent measures.
Statistics. Data from were analyzed using ANOVA followed by Student's t tests as appropriate, using SYSTAT v. 13 (SPSS). A criterion α = 0.05 was adopted to establish significance.
